Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A. Endocrine Society. Treatment of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(8):2807–31.
Article
CAS
Google Scholar
Carroll TB, Javorsky BR, Findling JW. Postsurgical recurrent Cushing disease: clinical benefit of early intervention in patients with normal urinary free cortisol. Endocr Pract. 2016;22(10):1216–23.
Article
Google Scholar
Minniti G, Osti M, Jaffrain-Rea ML, Esposito V, Cantore G, Maurizi ER. Long-term follow-up results of postoperative radiation therapy for Cushing’s disease. J Neuro-Oncol. 2007;84(1):79–84.
Article
Google Scholar
Hamrahian AH, Yuen KCJ, Hoffman AR. AACE neuroendocrine and pituitary scientific committee. AACE/ACE disease state clinical review: medical management of Cushing disease. Endocr Pract. 2014;20(7):746–57.
Article
Google Scholar
Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome. J Clin Endocrinol Metab. 2012;97(6):2039–49.
Article
CAS
Google Scholar
Fleseriu M, Findling JW, Koch CA, Schlaffer S-M, Buchfelder M, Gross C. Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing’s disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone. J Clin Endocrinol Metab. 2014;99(10):3718–27.
Article
CAS
Google Scholar
Katznelson L, Loriaux DL, Feldman D, Braunstein GD, Schteingart DE, Gross C. Global clinical response in Cushing’s syndrome patients treated with mifepristone. Clin Endocrinol. 2014;80(4):562–9.
Article
CAS
Google Scholar
Yuen KC, Williams G, Kushner H, Nguyen D. Association between mifepristone dose, efficacy, and tolerability in patients with Cushing syndrome. Endocr Pract. 2015;21(10):1087–92.
Article
Google Scholar
Wallia A, Colleran K, Purnell JQ, Gross C, Molitch ME. Improvement in insulin sensitivity during mifepristone treatment of Cushing syndrome: early and late effects. Diabetes Care. 2013;36(9):e147–e8.
Article
Google Scholar
Fein HG, Vaughan TB 3rd, Kushner H, Cram D, Nguyen D. Sustained weight loss in patients treated with mifepristone for Cushing’s syndrome: a follow-up analysis of the SEISMIC study and long-term extension. BMC Endocr Disord. 2015;15:63.
Article
CAS
Google Scholar
Carroll T, Findling JW. The use of mifepristone in the treatment of Cushing’s syndrome. Drugs Today (Barc). 2012;48(8):509–18.
CAS
Google Scholar
Fleseriu M, Molitch ME, Gross C, Schteingart DE, Vaughan TB 3rd, Biller BM. A new therapeutic approach in the medical treatment of Cushing’s syndrome: glucocorticoid receptor blockade with mifepristone. Endocr Pract. 2013;19(2):313–26.
Article
Google Scholar
Bhattacharyya A, Kaushal K, Tymms DJ, Davis JR. Steroid withdrawal syndrome after successful treatment of Cushing’s syndrome: a reminder. Eur J Endocrinol. 2005;153(2):207–10.
Article
CAS
Google Scholar
Raff H, Sharma ST, Nieman LK. Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing’s syndrome, adrenal insufficiency, and congenital adrenal hyperplasia. Compr Physiol. 2014;4(2):739–69.
Article
Google Scholar
Schrier RW. Body water homeostasis: clinical disorders of urinary dilution and concentration. J Am Soc Nephrol. 2006;17(7):1820–32.
Article
CAS
Google Scholar
Korlym® (mifepristone) 300 mg tablets [prescribing information]. Menlo Park, CA: Corcept Therapeutics Incorporated; 2019. https://www.korlym.com/wp-content/uploads/2018/01/K-00017-NOV-2019_electronic-PI_r8_FINAL.pdf. Accessed 24 June 2020.
Rushworth RL, Torpy DJ, Falhammar H. Adrenal crisis. N Engl J Med. 2019;381(9):852–61.
Article
CAS
Google Scholar
Takasu N, Komiya I, Nagasawa Y, Asawa T, Yamada T. Exacerbation of autoimmune thyroid dysfunction after unilateral adrenalectomy in patients with Cushing’s syndrome due to an adrenocortical adenoma. N Engl J Med. 1990;322(24):1708–12.
Article
CAS
Google Scholar
Noguchi Y, Tamai H, Fujisawa K, Nagano J, Mukuta T, Komaki G, Masubayashi S, Kubo C, Torisu M, Nakagaki H, Imayama S. Systemic lupus erythematosus after pituitary adenomectomy in a patient with Cushing’s disease. Clin Endocrinol. 1998;48(5):670–2.
Article
CAS
Google Scholar
Senecal JL, Uthman I, Beauregard H. Cushing’s disease-induced remission of severe rheumatoid arthritis. Arthritis Rheum. 1994;37(12):1826.
Article
CAS
Google Scholar
Torpy DJ, Mullen N, Ilias I, Nieman LK. Association of hypertension and hypokalemia with Cushing’s syndrome caused by ectopic ACTH secretion: a series of 58 cases. Ann N Y Acad Sci. 2002;970:134–44.
Article
CAS
Google Scholar
Howlett TA, Drury PL, Perry L, Doniach I, Rees LH, Besser GM. Diagnosis and management of ACTH-dependent Cushing’s syndrome: comparison of the features in ectopic and pituitary ACTH production. Clin Endocrinol. 1986;24(6):699–713.
Article
CAS
Google Scholar
Ulick S, Wang JZ, Blumenfeld JD, Pickering TG. Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab. 1992;74(5):963–7.
CAS
Google Scholar
US Department of Health and Human Services, US Department of Agriculture. Dietary Guidelines for Americans, 2015–2020. 8th edition. 2015. https://health.gov/dietaryguidelines/2015/resources/2015-2020_Dietary_Guidelines.pdf. Accessed July 29, 2019.
Berger C, Boggavarapu N, Norlin E, Queckborner S, Hornaeus K, Falk A, Engman M, Ramstrom M, Lalitkumar PGL, Gemzell-Danielsson K. Molecular characterization of PRM-associated endometrial changes, PAEC, following mifepristone treatment. Contraception. 2018;98(4):317–22.
Article
CAS
Google Scholar
Mutter GL, Bergeron C, Deligdisch L, Ferenczy A, Glant M, Merino M, Williams AR, Blithe DL. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol. 2008;21(5):591–8.
Article
CAS
Google Scholar
Carroll TB, Ioffe O, Spitz IM, Gross C, Cram D, Hamrahian AH. Endometrial effects of long-term mifepristone (MIFE) treatment of Cushing’s syndrome: results from the SEISMIC studies. Endocr Rev. 2013;34(suppl 1):SUN-52.
Fiscella J, Bonfiglio T, Winters P, Eisinger SH, Fiscella K. Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone. Hum Pathol. 2011;42(7):947–53.
Article
CAS
Google Scholar
Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol. 2003;101(2):243–50.
CAS
Google Scholar
Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol. 2005;12(3):227–33.
Article
Google Scholar
Basina M, Liu H, Hoffman AR, Feldman D. Successful long-term treatment of Cushing disease with mifepristone (RU486). Endocr Pract. 2012;18(5):e114–e20.
Article
Google Scholar
Guarda FJ, Findling J, Yuen KCJ, Fleseriu M, Nachtigall LB. Mifepristone increases thyroid hormone requirements in patients with central hypothyroidism: a multicenter study. J Endocr Soc. 2019;3(9):1707–14.
Article
CAS
Google Scholar
Heikinheimo O, Ranta S, Grunberg S, Lahteenmaki P, Spitz IM. Alterations in the pituitary-thyroid and pituitary-adrenal axes--consequences of long-term mifepristone treatment. Metabolism. 1997;46(3):292–6.
Article
CAS
Google Scholar
Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, Pessah-Pollack R, Singer PA, Woeber KA. American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on hypothyroidism in adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18(6):988–1028.
Article
Google Scholar
Bekkering GE, Agoritsas T, Lytvyn L, Heen AF, Feller M, Moutzouri E, Abdulazeem H, Aertgeerts B, Beecher D, Brito JP, Farhoumand PD, Singh Ospina N, Rodondi N, van Driel M, Wallace E, Snel M, Okwen PM, Siemieniuk R, Vandvik PO, Kuijpers T, Vermandere M. Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. BMJ. 2019;365:l2006.
Article
CAS
Google Scholar
US Center for Drug Evaluation and Research. Clinical review: mifepristone tablets. NDA application number: 202107Orig1s000. 2012. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000MedR.pdf. Accessed June 24, 2019.
Eliquis® (apixaban) tablets, for oral use [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2019. https://packageinserts.bms.com/pi/pi_eliquis.pdf. Accessed 24 June 2020.
Xarelto® (rivaroxaban) tablets, for oral use [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2020. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf. Accessed 24 June 2020.
Jang GR, Wrighton SA, Benet LZ. Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes. Biochem Pharmacol. 1996;52(5):753–61.
Article
CAS
Google Scholar
He K, Woolf TF, Hollenberg PF. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486). J Pharmacol Exp Ther. 1999;288(2):791–7.
CAS
Google Scholar
Gardiner P, Schrode K, Quinlan D, Martin BK, Boreham DR, Rogers MS, Stubbs K, Smith M, Karim A. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol. 1989;29(4):342–7.
Article
CAS
Google Scholar
Castinetti F, Fassnacht M, Johanssen S, Terzolo M, Bouchard P, Chanson P, Do Cao C, Morange I, Pico A, Ouzounian S, Young J, Hahner S, Brue T, Allolio B, Conte-Devolx B. Merits and pitfalls of mifepristone in Cushing’s syndrome. Eur J Endocrinol. 2009;160(6):1003–10.
Article
CAS
Google Scholar
Sack PA, Smith JJ. Mifepristone therapy prior to pituitary surgery in Cushing disease prevented need for long-term glucocorticoid replacement. Endocr Pract. 2018;39(2 suppl): SAT-578.
Saroka RM, Kane MP, Robinson L, Busch RS. No postoperative adrenal insufficiency in a patient with unilateral cortisol-secreting adenomas treated with mifepristone before surgery. Clin Med Insights Endocrinol Diab. 2016;9:31–6.
Google Scholar
Magaji V, Park SY, Mastoris K, Bucciarelli M, Beman S. Mifepristone utilization in Cushing’s from large bilateral adrenal adenoma prior to surgery. J Endocrinol Metab. 2015;5(3):226–8.
Article
CAS
Google Scholar
Moraitis AG, Auchus RJ. Clinical and hormonal response to mifepristone therapy in 2 patients with ACTH-independent Cushing syndrome. ACCE Clin Case Rep. 2015;1(3):e204–e7.
Google Scholar
Cohan P, East HE, Galati SJ, Mercado JU, Lim PJ, Lamerson M, Smith JJ, Peters AL, Yuen KCJ. Mifepristone treatment in four cases of primary bilateral macronodular adrenal hyperplasia (BMAH). J Clin Endocrinol Metab. 2019;104(12):6279–90.
Article
Google Scholar
Debono M, Chadarevian R, Eastell R, Ross RJ, Newell-Price J. Mifepristone reduces insulin resistance in patient volunteers with adrenal incidentalomas that secrete low levels of cortisol: a pilot study. PLoS One. 2013;8(4):e60984.
Article
CAS
Google Scholar
Banerjee RR, Marina N, Katznelson L, Feldman BJ. Mifepristone treatment of Cushing’s syndrome in a pediatric patient. Pediatrics. 2015;136(5):e1377–e81.
Article
Google Scholar
Newfield RS, Spitz IM, Isacson C, New MI. Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin Endocrinol. 2001;54(3):399–404.
Article
CAS
Google Scholar
Targher G, Bertolini L, Rodella S, Zoppini G, Zenari L, Falezza G. Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. Clin Endocrinol. 2006;64(3):337–41.
Article
CAS
Google Scholar
Ragucci E, Nguyen D, Lamerson M, Moraitis AG. Effects of mifepristone on nonalcoholic fatty liver disease in a patient with a cortisol-secreting adrenal adenoma. Case Rep Endocrinol 2017;2017:6161348.
Moraitis A, Feelders R, Gordon M, Iacuaniello D, Kargi A, Pivonello R. IGF-1 levels in patients with hypercortisolism and effects of medical therapy with relacorilant, a selective cortisol modulator. Endocr Pract. 2018;24(suppl 1):318–9.
Google Scholar
Gordon MB, Spiller KL, Bunta R, Gordon MS. Persistent acromegaly controlled on pegvisomant with co-existing non-ACTH dependent Cushing’s syndrome (CS) due to bilateral adrenal adenomas with dramatic clinical response to mifepristone. Endocr Rev. 2016;37(2 suppl 1):SUN 555.
Page ST, Krauss RM, Gross C, Ishida B, Heinecke JW, Tang C, Amory JK, Schaefer PM, Cox CJ, Kane J, Purnell JQ, Weinstein RL, Vaisar T. Impact of mifepristone, a glucocorticoid/progesterone antagonist, on HDL cholesterol, HDL particle concentration, and HDL function. J Clin Endocrinol Metab. 2012;97(5):1598–605.
Article
CAS
Google Scholar